Atrogin-1 Affects Muscle Protein Synthesis and Degradation When Energy Metabolism Is Impaired by the Antidiabetes Drug Berberine
暂无分享,去创建一个
[1] D. James,et al. Berberine, a Natural Plant Product, Activates AMP-Activated Protein Kinase With Beneficial Metabolic Effects in Diabetic and Insulin-Resistant States , 2006, Diabetes.
[2] K. Nair,et al. Synthesis rate of muscle proteins, muscle functions, and amino acid kinetics in type 2 diabetes. , 2002, Diabetes.
[3] S. Fujita,et al. Aerobic Exercise Overcomes the Age-Related Insulin Resistance of Muscle Protein Metabolism by Improving Endothelial Function and Akt/Mammalian Target of Rapamycin Signaling , 2007, Diabetes.
[4] W. Mitch,et al. Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy. , 2010, Journal of the American Society of Nephrology : JASN.
[5] G. Yancopoulos,et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. , 2004, Molecular cell.
[6] W. Mitch,et al. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. , 2004, The Journal of clinical investigation.
[7] W. Mitch,et al. PTEN Expression Contributes to the Regulation of Muscle Protein Degradation in Diabetes , 2007, Diabetes.
[8] Jianping Ye,et al. Berberine improves glucose metabolism through induction of glycolysis. , 2008, American journal of physiology. Endocrinology and metabolism.
[9] Yuebo Zhang,et al. Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARgamma pathway. , 2006, Biochemical and biophysical research communications.
[10] W. Mitch,et al. Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. , 2004, Journal of the American Society of Nephrology : JASN.
[11] D J Glass,et al. Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy , 2001, Science.
[12] W. Mitch,et al. Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice. , 2009, The Journal of clinical investigation.
[13] W. Mitch,et al. IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. , 2009, Journal of the American Society of Nephrology : JASN.
[14] P. Gachon,et al. Impaired anabolic response of muscle protein synthesis is associated with S6K1 dysregulation in elderly humans , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[15] B. Turk,et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. , 2008, Molecular cell.
[16] W. Mitch,et al. Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. , 2006, Endocrinology.
[17] A. Goldberg,et al. Metabolic acidosis stimulates muscle protein degradation by activating the adenosine triphosphate-dependent pathway involving ubiquitin and proteasomes. , 1994, The Journal of clinical investigation.
[18] Marco Sandri,et al. Foxo Transcription Factors Induce the Atrophy-Related Ubiquitin Ligase Atrogin-1 and Cause Skeletal Muscle Atrophy , 2004, Cell.
[19] B. Warner,et al. Effect of insulin on amino acid uptake and protein turnover in skeletal muscle from septic rats. Evidence for insulin resistance of protein breakdown. , 1987, Archives of surgery.
[20] L. Phillips,et al. Muscle wasting in insulinopenic rats results from activation of the ATP-dependent, ubiquitin-proteasome proteolytic pathway by a mechanism including gene transcription. , 1996, The Journal of clinical investigation.
[21] S. Fujita,et al. Supraphysiological hyperinsulinaemia is necessary to stimulate skeletal muscle protein anabolism in older adults: evidence of a true age-related insulin resistance of muscle protein metabolism , 2009, Diabetologia.
[22] N. Offner,et al. The initiation factor eIF3‐f is a major target for Atrogin1/MAFbx function in skeletal muscle atrophy , 2008, The EMBO journal.
[23] L. Kuller,et al. Excessive Loss of Skeletal Muscle Mass in Older Adults With Type 2 Diabetes , 2009, Diabetes Care.
[24] A. Goldberg,et al. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. , 2006, Journal of the American Society of Nephrology : JASN.
[25] M. Lane,et al. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. , 2009, American journal of physiology. Endocrinology and metabolism.
[26] M. Gu,et al. Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK. , 2006, Biochimica et biophysica acta.
[27] Yuebo Zhang,et al. Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARγ pathway , 2006 .
[28] A. Goldberg,et al. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. , 2004, American journal of physiology. Endocrinology and metabolism.
[29] D. James,et al. Berberine and Its More Biologically Available Derivative, Dihydroberberine, Inhibit Mitochondrial Respiratory Complex I , 2008, Diabetes.
[30] A. Goldberg,et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[31] M. Delp,et al. Site- and compartment-specific changes in bone with hindlimb unloading in mature adult rats. , 2002, Bone.
[32] K. Nair,et al. Effect of insulin on human skeletal muscle mitochondrial ATP production, protein synthesis, and mRNA transcripts , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[33] C. Lang,et al. AMP-activated protein kinase agonists increase mRNA content of the muscle-specific ubiquitin ligases MAFbx and MuRF1 in C2C12 cells. , 2007, American journal of physiology. Endocrinology and metabolism.
[34] Michiaki Yamashita,et al. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. , 2007, The Journal of clinical investigation.